Introduction
============

Neurodevelopmental disorders are a group of conditions that present in early life and are characterized by the failure to meet typical developmental milestones. These disorders affect a significant fraction of the population: 15% of children aged 3 to 17 years old were reported to have a developmental disability in the years 2006 to 2008 ([@B14]). The current Diagnostic and Statistical Manual of Mental Disorders (DSM-V) categorizes NDDs into six groups: intellectual disabilities (IDs), learning disorders, communication disorders, ASDs, ADHDs, and motor disorders ([@B6]). There is often overlap between these groups; for example, 31.6% of patients with ASD also fulfill the diagnostic criteria for ID ([@B23]). In addition, NDDs are associated with many co-morbidities, including but not limited to: epilepsy, mood disorders, breathing abnormalities, sleep problems, and gastrointestinal issues ([@B75]; [@B32]). Individuals with NDDs can struggle to develop interpersonal relationships and face immense challenges in school and in the workforce. Treatment options remain limited and there is a great need to identify novel points of intervention to improve the quality of life of these patients.

A growing body of literature suggests that NDDs arise from complex interactions between the environment and the genome ([@B132]; [@B54]). In some cases, NDDs can be traced to genetic abnormalities such as point mutations, gene deletions/duplications, or chromosomal rearrangements. Examples of such disorders include Down syndrome, RTT, Fragile X syndrome, and Angelman syndrome. Although a clear genetic cause is often rare, monogenetic disorders have helped to identify proteins and pathways that are required for proper neuronal development and maintenance. Interestingly, many genes that have been associated with syndromic and non-syndromic NDDs can be clustered into pathways involved in synaptic structure and function ([@B119]; [@B124]). In this review, we focus on the metabotropic glutamate receptor 7 (mGlu~7~), a GPCR that serves as an important regulator of synaptic transmission and plasticity. We will summarize current literature suggesting the involvement of mGlu~7~ in NDDs and discuss its potential utility as a novel therapeutic target.

Metabotropic Glutamate Receptors
================================

mGlu~7~ is one of eight subtypes of mGlu that are expressed throughout the body. The mGlu receptors are a family of Class C GPCRs that are further divided into three groups based on their sequence homology, signaling pathways, and ligand selectivity. Group I includes mGlu~1~ and mGlu~5~, Group II includes mGlu~2~ and mGlu~3~, and Group III includes mGlu~4~, mGlu~6~, mGlu~7~, and mGlu~8~ ([@B87]). Characteristic of Class C GPCRs, all mGlu receptors consist of a large *N*-terminal ligand binding domain, a cysteine-rich domain, a heptahelical domain, and a C-terminal domain; G proteins interact with intracellular loops and the C-terminus of the receptors.

The large extracellular *N*-terminal ligand binding domain consists of two lobes that sit on top of one another, similar to a Venus flytrap. This structural similarity earned it the name VFD. Glutamate, the endogenous ligand for mGlu receptors, binds to a cleft in between the two lobes of the VFD ([@B67]; [@B101]; [@B87]). The mGlu receptors function as constitutive dimers ([@B102]; [@B35]), and dimerization primarily occurs at the level of the VFDs ([@B67]; [@B57]; [@B101]; [@B72]). The VFDs can exist in three different states within the dimer: open-open, open-closed, and closed-closed. The open-open state is the inactive state, and upon glutamate binding to the cleft of the VFD, the VFD closes and receptor activation occurs. Ligand binding to one VFD results in the open-closed conformation, whereas ligand binding to both VFDs results in the closed-closed conformation ([@B102]; [@B85]). It is suggested that glutamate binding to one VFD alone is sufficient for activation (open-closed), but that full activation is achieved when both VFDs are ligand bound (closed-closed) ([@B65]). Although mGlu~7~ has been historically predicted to act as a homodimer, it has also been postulated that the receptor enacts some of its function through hetero-dimerization with other receptors, such as mGlu~8~ ([@B33]; [@B60]).

The cysteine-rich domain contains nine cysteine residues linked by disulfide bonds that are critical for propagating signals from the VFDs to the rest of the receptor ([@B106]; [@B85]). After glutamate binding, signals are transduced through the cysteine-rich domain to the heptahelical domain where conformational changes allow for G protein coupling ([@B67]; [@B128]; [@B12]; [@B85]; [@B35]). mGlu~7~ and the other Group III mGlu receptors couple to G~i/o~, which inhibits adenylyl cyclase activity and reduces intracellular cAMP concentrations ([@B87]). Furthermore, mGlu~7~ activation can result in K^+^ influx via G~βγ~-mediated opening of GIRK ion channels, and inhibition of Ca^2+^ currents through N- and P/Q- type calcium channels ([@B82], [@B81]; [@B77]).

mGlu~7~ is the most widely expressed mGlu receptor in the CNS with relatively high expression in the amygdala, hippocampus, and hypothalamus ([@B62]). There are 15 splice variants of *GRM7*, six of which are predicted to be protein coding ([@B135]). The two major isoforms, mGlu~7a~ and mGlu~7b~, differ at their C-termini and it is hypothesized that these distinct C-terminal tails mediate different protein-protein interactions ([@B29]). While mGlu~7a~ and mGlu~7b~ are primarily expressed in the CNS ([@B42]; [@B24]; [@B66]), isoform specificity has been observed in peripheral tissues such as the testes, trachea, uterus, and salivary gland ([@B110]). In the CNS, mGlu~7~ receptors are primarily localized to presynaptic active zones in neurons where they can act as auto- or hetero-receptors to inhibit the release of their endogenous ligand, glutamate, the main excitatory neurotransmitter or GABA, the main inhibitory neurotransmitter, respectively ([@B113]; [@B19]; [@B27]; [@B118]; [@B87]). Compared to the other Group III mGlu receptors, mGlu~7~ exhibits an extremely low affinity for glutamate (high μM to mM as opposed to high nM to low mM for the other Group III mGlu receptors). Because of this low affinity, it has been suggested that mGlu~7~ functions as an "emergency brake" in the case of elevated glutamate levels ([@B87]). This idea is supported by the observation that mGlu~7~ knockout mice exhibit spontaneous seizures under certain contexts ([@B109]).

Current mGlu~7~ Tool Compounds
==============================

Research to investigate mGlu~7~ biology has been limited, in part, due to the lack of selective tool compounds. Many of the currently existing compounds do not demonstrate high selectivity, desired pharmacokinetic properties, and/or high potency. Here, we review compounds currently available that will be mentioned in subsequent sections (compound properties at Group III mGlu receptors listed in Table [1](#T1){ref-type="table"} and structures in Figure [1](#F1){ref-type="fig"}).

###### 

Summary of current tool compounds used to study mGlu~7~.

  Name (\#)            Type                     mGlu~7~ pEC~50~/pIC~50~   mGlu~8~ pEC~50~/pIC~50~   mGlu~4~ pEC~50~/pIC~50~   mGlu~6~ pEC~50~/pIC~50~   Source
  -------------------- ------------------------ ------------------------- ------------------------- ------------------------- ------------------------- ------------------------
  L-AP4 **(1)**        Orthosteric agonist      3.47 (PIH)                6.53 (PIH)                7.00 (PIH)                5.62 (PIH)                [@B2]; [@B111]
                                                3.61 (Ca^2+^)             6.53 (Ca^2+^)             6.89 (Ca^2+^)             6.00 (Ca^2+^)             
  LSP4-2022 **(2)**    Orthosteric agonist      4.34 (Ca^2+^)             4.54 (Ca^2+^)             6.96 (Ca^2+^)             5.36 (Ca^2+^)             [@B2]; [@B48]; [@B111]
  LSP1-2111 **(3)**    Orthosteric agonist      4.28 (PIH)                4.18 (PIH)                5.66 (PIH)                5.77 (PIH)                [@B111]
                                                4.00 (Ca^2+^)             4.71 (Ca^2+^)             6.05 (Ca^2+^)             5.49 (Ca^2+^)             
  LSP2-9166 **(4)**                             5.71 (Ca^2+^)             4.25 (Ca^2+^)             7.22 (Ca^2+^)             Not reported              [@B2]
  VU0422288 **(5)**    Group III PAM            6.85 (Ca^2+^)             6.93 (Ca^2+^)             6.98 (Ca^2+^)             Not reported              [@B55]
  VU0155094 **(6)**    Group III PAM            5.80 (Ca^2+^)             6.07 (Ca^2+^)             5.48 (Ca^2+^)             Not reported              [@B55]
  ADX88178 **(7)**     mGlu~4/8~ PAM            \>4.52 (Ca^2+^)           5.66 (Ca^2+^)             8.46 (Ca^2+^)             \>5                       [@B70]
  ADX71743 **(8)**     mGlu~7~ NAM              7.20 (human, Ca^2+^)      Inactive                  Inactive                  Inactive                  [@B59]
                                                7.06 (rat, Ca^2+^)        Inactive                  Inactive                  Inactive                  
  AMN082 **(9)**       Allosteric agonist       6.59 (GTPγS)              \>5 (GTPγS)               \>5 (GTPγS)               \>5 (GTPγS)               [@B83]
  XAP044 **(10)**      Antagonist               5.26 (cAMP)               4.48 (cAMP)               Inactive                  Inactive                  [@B44]
                                                5.55 to 5.46 (GTPγS)                                                                                    
  LY341495 **(11)**    Orthosteric antagonist   6.00 (cAMP)               6.76 (cAMP)               4.66 (cAMP)               Not reported              [@B61]
  MMPIP **(12)**       mGlu~7~ NAM              6.66 (cAMP)               \>5 (cAMP)                \>5 (cAMP)                Not reported              [@B122]
                                                7.15 (Ca^2+^)                                                                                           [@B88]
                                                6.14 (Thallium)                                                                                         [@B88]
  VU6010608 **(13)**   mGlu~7~ NAM              6.12 (Ca^2+^)             \>5 (Ca^2+^)              \>5 (Ca^2+^)              Inactive (\>5)            [@B104]
  VU6005649 **(14)**   mGlu~7/8~ PAM            6.19 (Ca^2+^)             5.59 (Ca^2+^)             \>5 (Ca^2+^)              Inactive                  [@B1]
                                                                                                                                                        

NAM, negative allosteric modulator; PAM, positive allosteric modulator; EC

50

, effective concentration 50; IC

50

, inhibitory concentration 50. Assay type is indicated in parenthesis: PIH, phosphatidylinositol hydrolysis; cAMP, cAMP accumulation; Ca

2

\+

, calcium mobilization; GTPγS, GTPγS binding.
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The development of mGlu~7~ PAMs and other activators has been a major challenge thus far. Many *in vitro* and *in vivo* studies examining the effects of mGlu~7~ potentiation have been performed with orthosteric Group III mGlu agonists such as L-2-amino-4-phosphonobutyric acid (L-AP4, **1**), LSP4-2022 (**2**), and LSP1-2111 (**3**). L-AP4 exhibits an *in vitro* potency (EC~50~) of 0.1, 337, and 0.29 μM at mGlu~4~, mGlu~7~, and mGlu~8~, respectively ([@B2]; [@B111]). Similarly, LSP4-2022 exhibits *in vitro* EC~50s~ of 0.11, 11.6, and 29.2 μM at mGlu~4~, mGlu~7~, and mGlu~8~, respectively ([@B2]; [@B48]; [@B111]), while a structurally-related analog, LSP1-2111, displays EC~50s~ of 2.2, 53, and 66 μM at each of these receptors ([@B111]). In addition to their relatively low potency at mGlu~7~, these orthosteric agonists have activity at the other Group III mGlu receptors, limiting their utility for the specific exploration of mGlu~7~ biology. Interestingly, the orthosteric mGlu~4/7~-preferring agonist LSP2-9166 is much more potent at mGlu~7~ compared to the other agonists described above (EC~50s~ = 0.06, 1.97, 55.6 μM at mGlu~4~, mGlu~7~, and mGlu~8~), but has yet to be investigated further in learning and memory paradigms ([@B2]; [@B51]; [@B71]).

Pan-Group III PAMs such as VU0422288 (**5**), which exhibits EC~50s~ of 108, 146, and 125 nM, for mGlu~4~, mGlu~7~, and mGlu~8~, respectively, and VU0155094 (**6**), 3.2, 1.5, and 0.9 μM ([@B55]) are also used. Additionally, VU6005649 **14**) is a dual mGlu~7/8~ PAM, with EC~50~ values of 650 nM and 2.6 μM at mGlu~7~ and mGlu~8~, respectively. In addition to its activity on mGlu~8~, VU6005649 displays off-target effects at the neurokinin-1 receptor (NK1). It is believed that these effects on NK1 may mediate sedative effects of this compound, which are observed in both wild-type and mGlu~7~ knockout animals ([@B1]). Because many of these tool compounds are not selective, they have been used concomitantly with other molecules, such as the mGlu~4/8~ PAM ADX88178 (**7**) or mGlu~7~ NAM ADX71743 (**8**), to confirm mGlu~7~-mediated effects ([@B70]; [@B59], [@B58]; [@B47]).

To date, only one mGlu~7~-selective allosteric agonist, AMN082 (**9**, EC~50~ = 260 nM), has been reported in the primary literature ([@B83]). AMN082 has been used for animal studies involving learning and memory and plasticity in the amygdala among other areas. However, it has been shown that AMN082 exhibits off-target effects, one of which is predicted to be inhibition of the serotonin transporter (SERT) ([@B120]; [@B3]), somewhat limiting its utility *in vivo* unless coupled with knockout studies.

In contrast to potentiators, there have been several mGlu~7~ selective antagonists and NAMs reported in the literature. The antagonist XAP044 (**10,** IC~50~ = 5.5 μM) binds within the VFD and has shown efficacy in both *in vivo* and *in vitro* experiments such as anxiety-, depression-, and fear-related behavioral tasks and electrophysiology ([@B44]). Originally labeled a Group II mGlu receptor antagonist (mGlu~2~ and mGlu~3~), LY341495 (**11**) was also found to have efficacy at mGlu~4~, mGlu~7~, and mGlu~8~ with IC~50s~ of 22, 0.99, and 0.173 μM, respectively ([@B61]) and has been used to study both groups of mGlu receptor since its discovery.

The mGlu~7~ NAM 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo\[4,5-*c*\]pyridin-4(5*H*)-one (MMPIP, **12**), reported in 2007, has been used for several studies involving mGlu~7~ ([@B122]). MMPIP is able to inhibit the response of L-AP4, but its efficacy was later shown to be context-dependent. For example, the potency (IC~50~) of MMPIP was 70 nM in a calcium mobilization assay utilizing cells expressing G~α15~ versus 718 nM in a thallium flux assay with cells expressing G~αi/o~, suggesting that its effects may be dependent on cellular background. Further, MMPIP was not effective in blocking an mGlu~7~-mediated depression of synaptic transmission in electrophysiological studies ([@B88]). ADX71743, reported in 2013, exhibits an IC~50~ of 63 and 88 nM at human and rat mGlu~7~, respectively ([@B59]). However, it also exhibits low activity at mGlu~2~ ([@B59]; [@B104]) and possesses an electrophilic ketone moiety that could result in covalent modification and subsequent off-target effects. Most recently, [@B104] have successfully developed a series of novel, chemically-distinct mGlu~7~ NAMs based upon a phenylbenzamide scaffold. One of the analogs, VU6010608 (**13**), exhibited modest potency (IC~50~ = 759 nM), but was cleared rapidly in rats (64.2 mL/min/kg) and exhibited low levels of brain penetration, making it challenging for *in vivo* CNS studies ([@B104]). These existing and emerging tools, coupled with mGlu~7~ knockout mice, have provided an initial toolbox to begin elucidation of the function of mGlu~7~ in normal and pathological conditions.

mGlu~7~ in Synaptic Transmission and Plasticity
===============================================

Inhibition of neurotransmitter release by mGlu~7~ is believed to be mediated by the inhibition of N-type and P/Q-type calcium channels through interactions with G~βγ~, PKC, PICK1, and reductions in intracellular cAMP ([@B82], [@B81]; [@B99]; [@B77]). Millan and Colleagues demonstrated that activation of cerebrocortical mGlu~7~ with L-AP4 inhibited N-type calcium channels in a PKA- and PKC-independent manner, suggesting that the inhibition was caused via interactions with G~βγ~. These authors also demonstrated that mGlu~7~-mediated decreases in cAMP could reduce spontaneous glutamate release in the cerebral cortex ([@B82]). Additionally, [@B100] demonstrated that P/Q-type calcium channels were inhibited via a PKC-dependent pathway, where G~i/o~ and/or G~βγ~ can stimulate the PLC pathway in cultured cerebellar granule cells. They also showed that the scaffolding protein, PICK1, facilitates the interaction between mGlu~7~ and PKC, and is required for receptor-mediated P/Q-type calcium channel inhibition in this context ([@B99]). In contrast, [@B77] demonstrated that mGlu~7~ inhibited hippocampal P/Q-type calcium channels in a PKC-independent manner. The mGlu~7~-mediated inhibition of glutamate release is also dependent on interactions with calmodulin (CaM), where activated CaM allows for the displacement of G~βγ~ from mGlu~7~ and the subsequent downregulation of calcium influx into the cell via calcium channel inhibition ([@B91]). Moreover, mGlu~7~'s interaction with MacMARCKS (macrophage myristoylated alanine--rich C--kinase substrate) competitively antagonizes CaM-mediated calcium channel inhibition ([@B10]).

mGlu~7~'s position within the active zone and its ability to modulate neurotransmitter release has led to numerous studies focused on its role in synaptic plasticity. Two major forms of synaptic plasticity include LTP and LTD, which are persistent changes in synaptic strength that are thought to be correlates of learning and memory ([@B13]; [@B125]). The role of mGlu~7~ in synaptic plasticity has been best characterized within the hippocampus at several distinct synapses. mGlu~7~ was first reported to mediate a form of LTD occurring in stratum radiatum interneurons within area CA3 ([@B68]). At excitatory synapses onto interneurons expressing calcium-permeable AMPA receptors, LTP could be induced by high frequency stimulation and blocked by the Group II and Group III mGlu antagonist, LY341495. Further pharmacological experiments confirmed the specific involvement of mGlu~7~: only a high concentration of L-AP4 depressed synaptic transmission at these synapses and a Group II mGlu agonist showed no effect. A similar form of plasticity was later described at mossy fiber inputs onto SLINs in area CA3 ([@B96]). At SLINs expressing calcium-permeable AMPA receptors, high frequency stimulation of mossy fibers induced an LTD that required mGlu~7~ activation and PKC-dependent depression of neurotransmitter release through P/Q-type voltage gated calcium channels ([@B96], [@B97]). Interestingly, in slices pre-treated with L-AP4, internalization of mGlu~7~ receptors revealed the ability of these synapses to undergo LTP instead of LTD in response to the same electrical stimulus. Surface expression of mGlu~7~, therefore, regulates the direction of plasticity at these synapses, making mGlu~7~ a "metaplastic switch" that can modulate feedforward inhibition in area CA3.

An additional class of interneurons in which mGlu~7~-mediated plasticity has been implicated is the OLM interneuron population within the stratum oriens of areas CA3 and CA1. At excitatory inputs onto OLM interneurons, mGlu~7~ expression is preferentially enriched ([@B113]) and proposed to be recruited by extracellular-leucine-rich repeat fibronectin type III domain containing 1, or ELFN1 ([@B130]). Sylwestrak and Ghosh demonstrated that ELFN1 knockdown in OLM interneurons decreases short-term facilitation and increases presynaptic release probability. Conversely, overexpression of ELFN1 in parvalbumin interneurons leads to short-term facilitation when these synapses typically undergo short-term depression ([@B123]). In slices from *Elfn1^-/-^* mice, presynaptic release probability, short term facilitation, and LTP are reduced in patch-clamp recordings from OLM interneurons ([@B130]). Although this evidence is indirect, it suggests that mGlu~7~ may be involved in these forms of synaptic plasticity since mGlu~7~ is likely to be a major regulator of presynaptic release probability at these synapses due to its recruitment by ELFN1.

In addition to its role as an autoreceptor on excitatory terminals, mGlu~7~ is also located on the terminals of interneurons within the hippocampus and modulates the release of GABA ([@B118]; [@B121]). This function of mGlu~7~ is required for LTP in wild-type animals at SC-CA1 synapses through a mechanism of disinhibition ([@B64]). Importantly, deficits in LTP at this particular synapse have been reported in several models of NDDs ([@B56]; [@B84]; [@B133]). At SC-CA1 synapses, mGlu~7~ is the only presynaptic mGlu receptor present in adult animals and activation of mGlu~7~ has been repeatedly shown to reduce field potentials at SC-CA1 ([@B8]; [@B7]; [@B55]). [@B64] demonstrated that mGlu~7~ activation by the agonist LSP4-2022 also reduces evoked inhibitory post-synaptic currents recorded from CA1 pyramidal cells. LTP induced by high-frequency stimulation was blocked by ADX71743, but only when GABAergic transmission was intact. Recently, we showed that a chemically distinct mGlu~7~ NAM, VU6010608, also blocked LTP induced by high-frequency stimulation at SC-CA1 synapses ([@B104]). Interestingly, hippocampal slices from *Grm7^-/-^* mice have been reported to exhibit similar levels of LTP when compared to WT controls, but decreased short-term potentiation following high-frequency stimulation ([@B16]). In these studies, slices from *Grm7^-/-^* mice showed reduced facilitation during the high-frequency train, an effect that was also seen with ADX71743 by [@B64]. The presence of LTP in *Grm7^-/-^* slices may be due to compensatory mechanisms during development, such as retained expression of mGlu~8~, which is present at SC-CA1 synapses earlier in development ([@B7]). Re-expression of mGlu~8~ is not unprecedented as the selective mGlu~8~ agonist (S)-3,4-DCPG was recently shown to reduce synaptic transmission at SC-CA1 in slices from pilocarpine-treated rats, but not in those of age-matched controls ([@B28]). While further studies will be needed to explain the current discrepancy between genetic and pharmacological approaches, these data indicate that mGlu~7~ regulates high-frequency transmission at SC-CA1 synapses. Recently, [@B76] demonstrated that prolonged activation of mGlu~7~ leads to potentiation of excitatory post-synaptic currents recorded by pyramidal cells in CA1. This potentiation of neurotransmitter release is dependent on PLC and the vesicle release proteins Munc13-2 and Rim1α. These studies indicate that, under conditions of high-frequency stimulation, mGlu~7~ activation favors potentiation of excitatory transmission, which could be an additional mechanism by which mGlu~7~ modulates long-term plasticity in the hippocampus.

Beyond the hippocampus, a role for mGlu~7~ in LTP has also been established within the amygdala. Synaptic plasticity in the hippocampus is believed to underlie associative learning and working memory, whereas plasticity in the amygdala is associated with aversion and emotional learning ([@B15]; [@B116]). The allosteric agonist AMN082 has been shown to block LTP at thalamo-amygdala synapses in slices from rats and mice ([@B39], [@B38]). This effect correlates with the ability of direct injection of AMN082 into the amygdala to block the acquisition of fear-potentiated startle behavior in rats ([@B39]) and fear learning in mice ([@B39], [@B38]). Interestingly, *Grm7^-/-^* mice exhibit a general deficit in fear learning and decreased LTP at thalamo-amygdala synapses ([@B38]). Reduction of LTP by both an agonist and gene ablation may be explained by AMN082's ability to cause rapid internalization of mGlu~7~ receptors ([@B98]). This would suggest that AMN082 can act as a functional antagonist by decreasing surface expression and, therefore, receptor signaling. This hypothesis is further supported by the ability of the mGlu~7~ antagonist XAP044 to block LTP within the amygdala, inhibit acquisition of conditioned fear, and reduce anxiety-like behavior ([@B44]). Together, these studies demonstrate that mGlu~7~ promotes plasticity within the amygdala, which is in line with its involvement in behaviors of fear and anxiety.

Role of mGlu~7~ in NDD-Associated Phenotypes
============================================

Core symptoms and comorbidities of NDDs can include, but are not limited to: cognitive impairment, seizures, mood disorders, social deficits, and motor impairments ([@B75]; [@B32]). Many studies have demonstrated that modulation of mGlu~7~ function via genetic and/or pharmacologic techniques is able to mimic some of these phenotypes in animal models, and these studies will be reviewed here.

Cognition
=========

mGlu~7~ knockout animals (*Grm7^-/-^*) show deficits in tasks that test cognitive functioning. In a conditioned taste aversion task, which measures amygdala-dependent aversive learning, mice were given saccharin along with an intraperitoneal injection of the control, saline, or LiCl, which evokes malaise. In this task, *Grm7^-/-^* mice did not associate the adverse effects of LiCl to saccharin in comparison to wild-type littermates, exhibiting a deficit in fear learning ([@B78]). In addition, [@B78] and [@B46], [@B45] demonstrated that *Grm7^-/-^* mice exhibit less freezing than wild-type animals in cued and contextual fear conditioning paradigms. Together, these results indicate a role for mGlu~7~ in aversion learning, and also suggest that the loss of mGlu~7~ causes impairments in these learning paradigms.

mGlu~7~ has also been demonstrated to play a role in cognitive tasks that do not rely on fearful or aversive stimuli. [@B17] showed that *Grm7^-/-^* mice exhibit impaired short-term working memory in 4- and 8-arm radial maze tasks, committing more errors (visits to previously baited arms or un-baited arms) than their wild-type counterparts. Conversely, *Grm7^-/-^* mice performed similarly to wild-type animals in radial maze tasks when they were modified to assess long-term memory. Furthermore, both [@B17] and [@B45] have reported that the loss of mGlu~7~ causes increased latency to locate a platform in the Morris water maze task of spatial memory. Interestingly, *Grm7^-/-^* mice performed similarly to wild-type animals after increased training and in un-cued trials ([@B17]). Together, these data demonstrate that mGlu~7~ may play specific roles in tasks involving working and spatial memory.

Pharmacological studies have further confirmed a role for mGlu~7~ in learning and memory. [@B52] showed that administration of MMPIP, an mGlu~7~ NAM, to wild-type mice reduced performance in object recognition and location tasks, suggesting that mGlu~7~ is also involved in recognition memory. MMPIP also attenuates conditioned taste aversion learning in rats ([@B63]). Interestingly, MMPIP improved cognitive performance in Y-maze and object recognition assays in a mouse model of neuropathic pain with no effect on sham-treated animals ([@B92]). As discussed above, MMPIP exhibits cellular background-dependent differences *in vitro*, and also had no effect in an electrophysiological study of at SC-CA1 synapses in the hippocampus ([@B88]), which may complicate interpretation of *in vivo* data. Inhibition of mGlu~7~ with the antagonist XAP044 also resulted in reduced freezing in mice during a contextual fear conditioning task, further supporting a role for mGlu7 in amygdala function ([@B44]). Activation of mGlu~7~ with an allosteric agonist, AMN082, has been shown to modulate both the acquisition and extinction of conditioned fear, though the results seem to contradict findings from studies performed with XAP044 and *Grm7^-/-^* animals ([@B39], [@B38]; [@B46]; [@B115]; [@B30]; [@B44]). Administration of AMN082 impairs the acquisition and enhances the extinction of fear learning ([@B39], [@B38]; [@B115]; [@B30]), but knockout animals exhibit similar phenotypes in conditioned fear paradigms ([@B46]; [@B38]). AMN082 appears to exhibit a task-dependent phenotype, where mGlu~7~ activation facilitates between-session extinction, but not within-session extinction in a fear conditioning model ([@B131]; [@B38]). AMN082 was also shown to have effects in social fear; it impaired extinction and recall when administered prior to the social fear extinction task, but not when given before social fear conditioning ([@B117]). However, [@B3] demonstrated that AMN082 produced similar sleep-wake and hypothermia phenotypes in *Grm7^-/-^* and wild-type mice, suggesting that there may be off-target effects elicited by the compound. Additionally, administration of VU6005649, an mGlu~7/8~ PAM, to wild-type mice, increases freezing in contextual fear conditioning ([@B1]).

Seizures
========

Seizures are often present in patients with NDDs, and mGlu~7~ and its interacting proteins have been implicated in seizure activity. [@B109] observed that *Grm7^-/-^* mice suffered from spontaneous sensory stimulus-seizures and were also more susceptible to subconvulsant doses of PTZ and bicuculline than their heterozygous or wild-type littermates. In addition, reduction of mGlu~7~ activity with the NAM ADX71743 was sufficient to induce absence seizures ([@B126]). Disruption of proteins that interact with mGlu~7~ can also induce seizures in mice ([@B11]; [@B130]). For example, PICK1 is a PDZ-domain containing protein that interacts with the C-terminus of mGlu~7~. The protein-protein interaction between PICK1 and mGlu~7~ is important for stable mGlu~7~ cell surface expression, proper trafficking of mGlu~7~ to presynaptic active zones, and also for inhibition of P/Q-type calcium channels. Disruption of the interaction between PICK1 and mGlu~7~ appears to interfere with mGlu~7~'s inhibitory activity via decreased cell surface stability/expression or improper signaling and trafficking, resulting in a seizure phenotype in mice ([@B99]; [@B11]; [@B136]).

As mentioned previously, ELFN1 is a transmembrane protein that has been demonstrated to recruit mGlu~7~ to distinct cell populations in the hippocampus and cortex ([@B130]). Most recently, ELFN1 was also shown to be a trans-synaptic allosteric modulator of Group III mGlu receptors; receptor modulation occurs through an ELFN1-mediated alteration of G-protein coupling efficiency to the Group III mGlu receptors ([@B34]). Of note, ELFN1 mutations clustered in the region required for mGlu~7~ recruitment have been found in patients with epilepsy and ADHD ([@B31]; [@B130]), and ELFN1 knockout (*Elfn1*^-/-^) animals exhibit a similar seizure phenotype to *Grm7*^-/-^ animals ([@B130]). Interestingly, *Elfn1*^-/-^ mice also exhibit ADHD-like phenotypes such as hyperactivity and impulsivity. [@B31] showed that *Elfn1*^-/-^ animals display hyperlocomotion and increased activity in an open field. Administration of amphetamine to *Elfn1*^-/-^ mice was able to attenuate hyperlocomotion, similar to the effects of stimulant therapies for ADHD patients. [@B130] also demonstrated that *Elfn1*^-/-^ mice displayed more spontaneous activity than wild-type animals and also exhibited decreased immobility in a forced swim test, which are behaviors suggestive of hyperactivity. *Elfn1*^-/-^ mice spent more time in the open arms during an EPM task compared to wild-type littermates. These data are typically indicative of anxiolytic effects; however, *Elfn1*^-/-^ mice showed no preferences between the light and dark boxes of the light-dark box transition task. Based on this finding, the authors hypothesized that the results of the EPM were indicative of impulsivity. Together, these data suggest a role for the ELFN1-mGlu~7~ complex in seizures and in other disorders.

Mood Disorders
==============

mGlu~7~ modulation has also been demonstrated to impact behavioral models of mood disorders such as anxiety or depression, which are common comorbidities seen in NDDs ([@B79]). The amygdala and hippocampus, areas of high mGlu~7~ expression, are brain regions known for their importance in anti-anxiety and anti-depressive action ([@B114]). In comparison to cognitive tasks, where reductions in mGlu~7~ cause deficits, the loss of mGlu~7~ has been reported to result in anti-depressive and anxiolytic effects in these domains. For example, [@B26] showed that *Grm7*^-/-^ animals spend more time in the open arms than their wild-type counterparts in an EPM paradigm, demonstrating that the loss of the receptor causes anxiolytic activity. In a light-dark box task, the knockout animals have a reduced latency to enter a covered, dark compartment as well as an increased number of transitions into an open, brightly lit compartment than wild-type mice ([@B26]). [@B17] demonstrated that *Grm7*^-/-^ mice bury fewer marbles than wild-type animals in a marble burying task, which also measures anxiety-like behavior in rodents. ADX71743, the mGlu~7~-selective NAM, causes similar results in EPM, and reduces marble burying in wild-type mice ([@B59]). Administration of the NAM MMPIP also reduces marble burying, consistent with the *Grm7*^-/-^ phenotype ([@B92]). In tail suspension or forced swim tasks, where immobility is indicative of depression-like behavior, *Grm7*^-/-^ mice are less immobile than wild-type animals ([@B26]). In wild-type mice, the antagonist XAP044 also increases time in open arms in EPM and decreases immobility in tail suspension, recapitulating data from studies using knockout animals ([@B44]). In a mouse model of neuropathic pain, the NAM MMPIP also reduces immobility time during tail suspension ([@B92]). The mGlu~7~ agonist AMN082 reduces immobility in tail suspension and forced swim tasks, and MMPIP can block the effect of AMN082 ([@B90]; [@B93]). In summary, mGlu~7~ has been implicated in a range of behaviors in rodent models, many of which mimic those reported in rodent models of NDDs.

Genetic Associations Between mGlu~7~ and NDDs
=============================================

Genetic associations between NDDs and *GRM7*, the gene that encodes mGlu~7~ in humans, provide a link between experiments in rodent models and the clinical population. ASD affects as much as 1% of the world's population ([@B69]), and family studies have suggested that the heritability of ASD is about 83% ([@B108]), which indicates a strong genetic component. Heterozygous deletions in *GRM7* have been identified in three ASD patients by [@B43], and in one patient by [@B73]. The latter patient exhibited language and cognitive impairments as well as hyperactivity, stereotyped behaviors, and deficits in social interaction ([@B73]). An additional ASD patient with a *de novo* point mutation in *GRM7*, resulting in a change from arginine to glutamate at amino acid 622, was reported by [@B107]. This mutation affects the third transmembrane portion of the receptor. [@B134] identified the SNPs rs6782011 and rs779867, which encode a C to T change in intron 6 and a T to C or T to G change in intron 5 in *GRM7*, respectively. These two polymorphisms exhibited significant associations with ASD from a group of 22 ASD patients ([@B134]). In an Iranian cohort of 518 ASD patients, however, only rs779867 was identified as a SNP that associates *GRM7* with ASD ([@B89]). rs779867 is a T to C or T to G polymorphism in intron 5 hypothesized to have effects on a MRG protein binding motif. MRG motif-binding proteins are thought to bind chromatin and function in the regulation of gene transcription ([@B22]).

Attention deficit hyperactivity disorder is characterized by inattention, hyperactivity and impulsivity ([@B6]). Its estimated prevalence around the world is 7.2% in children and 3.4% in adults ([@B37]; [@B129]). A genome wide copy-number variation study revealed that rs7623055, which encodes a G to C or G to T change, was significantly associated with ADHD, and also identified six different deletions in *GRM7* in patients with ADHD ([@B36]). Additionally, rs37952452 was found to have some association with ADHD in a study of 202 patients in Korea, though it was not significantly associated when using a case-control approach ([@B94]). In contrast, neither rs37952452 nor rs7623055 were found to be significantly associated with ADHD in a later study ([@B4]). Interestingly, ADHD patients with the G/A genotype of rs37952452 showed an improved response to methylphenidate in comparison to those with the G/G genotype ([@B95]).

Rare mutations in *GRM7* have also been implicated in undiagnosed NDDs. Whole-exome sequencing in 31 consanguineous Arab families with developmental delay and/or intellectual disability revealed two families with mutations in *GRM7*. Two brothers in the same family were homozygous for a 461T/C variant, which results in the missense mutation I154T in the ligand binding domain of mGlu~7~. The same study also identified two siblings (brother and sister) who are compound heterozygous for the mutations 1972C/T and 2024C/A, which lead to missense mutations, R658W and T675Y, respectively, in the third transmembrane domain. These four patients share symptoms that include developmental delay, ID, brain malformations and seizures ([@B21]). In a different set of consanguineous families, exome sequencing identified two female cousins with the homozygous mutation 1757G/A, which results in a premature truncation of mGlu~7~ prior to its first transmembrane domain (W568^∗^). These patients exhibit seizures, profound ID, microcephaly and leukodystrophy ([@B105]). A search of the DECIPHER database ([@B40]) identified 69 patients with a deletion or duplication that included *GRM7*, although most of these also affected other genes. Three of these patients had a deletion or duplication restricted to the *GRM7* gene and their phenotypes are included in Table [2](#T2){ref-type="table"}.

###### 

Summary of *GRM7* mutations identified in NDD patients.

  Type             Chromosome 3 position   Nucleotide/protein change NM_00844.3         Location in transcript NM_00844.3   Zygosity                Phenotype                                                                      Source
  ---------------- ----------------------- -------------------------------------------- ----------------------------------- ----------------------- ------------------------------------------------------------------------------ -----------------
  Duplication      6209671--6981117                                                     5′ UTR and Exon 1                   Heterozygous            Behavioral abnormality, ID                                                     DECIPHER 289768
  Point mutation   6861849                 c.T461T \> C p.I154T                         Exon 1                              Homozygous              Developmental delay, seizures, hypotonia, atrophy, thin corpus callosum        [@B21]
  Deletion         7053179--7144453                                                     Intron 1/2 and Exon 2               Heterozygous            ASD                                                                            [@B43]
  Deletion         70664629--7172715                                                    Exon 2                              Heterozygous            ASD                                                                            [@B43]
  Deletion         7065422--7172715                                                     Exon 2                              Heterozygous            ASD                                                                            [@B43]
  Deletion         7257514--7442882                                                     Exons 3--5                          Heterozygous            Global developmental delay                                                     DECIPHER 356330
  Deletion         7221090--7524552                                                     Exons 3--7                          Heterozygous            ASD                                                                            [@B73]
  Point mutation   7578663                 c.1757 G \> A p.W586^∗^                      Exon 8                              Homozygous              Developmental delay, ID, microcephaly, seizures, leukodystrophy                [@B105]
  Point mutation   7578771                 c.1865 G \> A p.R622Q                        Exon 8                              Heterozygous            ASD                                                                            [@B107]
  Point mutation   7578878, 7578930        c.1972C \> T p.R658W, c.2024C \> A p.T675K   Exon 8                              Compound Heterozygous   Developmental delay, ID, hypotonia, hypomyelination, brain atrophy, seizures   [@B21]
  Duplication      7509664--7878406                                                     Exons 8--10                         Heterozygous            ID, microcephaly                                                               DECIPHER 288108
                                                                                                                                                                                                                                   

mGlu~7~ in *MECP2*-Related Disorders
====================================

Preclinical research in the NDD field has focused largely on mouse models of genetic syndromes due to their high construct validity. RTT is a monogenetic disorder in which mGlu~7~ has recently gained particular interest as a potential therapeutic target ([@B47]). RTT is a debilitating NDD affecting 1 in 20,000 births and is characterized by a period of normal development followed by sudden developmental regression and loss of acquired skills at 6 to 18 months of age. Following regression, RTT patients are burdened by life-long symptoms that include repetitive hand clasping, limited speech, intellectual disability, motor impairment, apneas, and epilepsy ([@B86]). The majority of RTT cases can be attributed to loss-of-function mutations in the X-linked gene *MECP2*, which encodes the transcriptional regulator methyl-CpG binding protein 2 (MeCP2) ([@B5]). Since this discovery, nearly two decades of research have yielded significant insight into the functions of MeCP2 within the brain. Of note, *MECP2* mutations have also been identified in patients with ASD and ID independent of a RTT diagnosis ([@B25]; [@B18]), suggesting that pathways involving MeCP2 may underlie NDDs more broadly. MeCP2 is canonically thought to repress gene transcription through binding to methylated CpG dinucleotides and recruiting repressor complexes; however, MeCP2 has also been shown to activate gene transcription and play roles in long-range regulation of chromatin structure, mRNA splicing and micro-RNA processing ([@B49]). Although MeCP2 is involved in prenatal and postnatal development ([@B127]; [@B112]; [@B9]), phenotypes of *Mecp2* knockout mice can be reversed if *Mecp2* expression is reintroduced in adult animals ([@B50]). Similarly, ablation of *Mecp2* expression in adult mice following normal development is sufficient to recapitulate the phenotype of constitutive *Mecp2* knockout mice ([@B80]). MeCP2 is thus critical for proper neuronal function throughout life and there exists a therapeutic window to improve disease severity, even at adult stages. These proof-of-concept studies have fueled programs to develop *MECP2* replacement strategies, along with parallel efforts to identify targets downstream of MeCP2 dysfunction that may be amenable to pharmacological manipulation.

mGlu~7~ is one of three mGlu receptors found to be decreased at the mRNA level in a RTT mouse model ([@B9]). These mGlu receptors represent a potential point of access to normalize synaptic function in RTT. Consistent with this initial report, we have shown that mGlu~7~ protein expression is significantly decreased in motor cortex autopsy samples from RTT patients compared to those of controls matched for age, sex, and postmortem interval ([@B47]). In global *Mecp*2 knockout mice, mGlu~7~ protein expression is decreased in a brain-region specific manner with a notable reduction in hippocampal synaptosomal fractions. This correlates with reduced depression of synaptic transmission at SC-CA1 synapses by LSP4-2022 in slices from RTT model mice, which can be restored by a PAM. Additionally, pre-application of two structurally distinct Group III mGlu receptor PAMs, VU0422288 and VU0155094, to slices was able to restore deficient LTP at SC-CA1 synapses in RTT model mice. Ablation of *Mecp2* selectively from GABAergic neurons is sufficient for LTP impairment ([@B20]); therefore, rescue of LTP by mGlu~7~ potentiation is consistent with the proposed model by which mGlu~7~-mediated inhibition of GABA release is required for LTP at SC-CA1 synapses ([@B64]).

At the behavioral level, mGlu~7~ potentiation by intraperitoneal administration of the brain penetrant PAM, VU0422288, is able to improve performance in assays of cognition in RTT model mice ([@B47]). While many studies in *Grm7^-/-^* mice have implicated a role for mGlu~7~ in learning and memory ([@B53]; [@B17]; [@B46]), this is the first report of mGlu~7~ activity being modulated in a positive direction to reverse a deficit in cognition. VU0422288 is also able to increase performance in a social novelty task and reduce the number of apneas detected by whole body plethysmography ([@B47]). These data suggest that mGlu~7~ potentiation may be a valid approach to address multiple RTT-associated symptom domains. It is important to note that these experiments used mice with a global deletion of *Mecp2*. As RTT is most commonly caused by *MECP2* point mutations in humans, it will be important to elucidate the effect of various point mutations on mGlu~7~ expression/function to identify patient subpopulations that would be predicted to benefit from an mGlu~7~ PAM.

mGlu~7~ has also been investigated for its therapeutic utility in a mouse of MDS. In contrast to RTT, MDS occurs when the region of the X chromosome containing *MECP2* is duplicated or triplicated, and is predicted to account for 1% of cases of unexplained X-linked intellectual disability ([@B74]). MDS patients present with infantile hypotonia, autism-associated symptoms, speech impairment, respiratory infections, and epilepsy ([@B103]). This disorder highlights the point that precise regulation of MeCP2 expression is required for normal brain function and that excess MeCP2 protein is detrimental. [@B41] tested whether mGlu~7~ protein levels are affected in *MeCP2-Tg1* mice, a model for MDS. Contrary to a hypothesis of bidirectional regulation, mGlu~7~ protein levels are unchanged in most brain regions in *MeCP2-Tg1* mice. Furthermore, neither genetic reduction of mGlu~7~ protein levels or administration of the mGlu~7~ NAM ADX71743 had any impact on anxiety and fear learning phenotypes in *MeCP2-Tg1* mice ([@B41]). These findings suggest that that mGlu~7~ expression/function may only be affected by MeCP2 hypofunction and not overexpression. More studies are warranted to understand the molecular interaction between MeCP2 and mGlu~7~ expression. This information will inform future drug development of mGlu~7~ PAMs for RTT and other NDDs in which *MECP2* mutations have been identified.

Conclusion
==========

Neurodevelopmental disorders are a prevalent group of disorders with limited treatment options and mGlu~7~ represents one potential access point for pharmacological intervention. *GRM7* gene disruptions identified in patients with NDDs provide clinical rationale for this approach. Pre-clinical studies in rodent models suggest that decreased mGlu~7~ function is sufficient to mimic phenotypes that correlate to NDD symptom domains and that positive modulation of mGlu~7~ activity can improve some deficits, specifically in a mouse model of RTT. However, NDDs are highly heterogeneous and are likely the result of unique molecular pathologies that converge to produce similar circuit and behavioral phenotypes. Therefore, further studies are needed to identify and understand which subpopulations may benefit from an mGlu~7~-mediated therapy. In parallel, further development of improved tool compounds will facilitate studies focused on understanding mGlu~7~ receptor function in brain circuits and behaviors associated with NDDs.
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ADHD

:   attention deficit hyperactivity disorder
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:   (+)-6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo\[*d*\]oxazol-4(5*H*)-one

ADX88178

:   5-methyl-*N*-(4-methylpyrimidin-2-yl)-4-(1*H*-pyrazol-4-yl)thiazol-2-amine

AMN082

:   *N,N′*-dibenzhydrylethane-1,2-diamine dihydrochloride

ASDs

:   autism spectrum disorders

CaM

:   calmodulin

cAMP

:   cyclic adenosine monophosphate

CNS

:   central nervous system

EC50

:   effective concentration 50

ELFN1

:   extracellular-leucine-rich repeat fibronectin type III domain containing 1

EPM

:   elevated plus maze

GABA

:   γ-aminobutyric acid

GIRK

:   G protein inwardly rectifying potassium channel

GPCR

:   G protein-coupled receptor

GTPγS

:   guanosine 5′-O-\[γ-thio\]triphosphate

IC50

:   inhibitory concentration 50

ID

:   intellectual disability

L-AP4

:   L-2-amino-4-phosphonobutyric acid

LiCl

:   lithium chloride

LSP1-2111

:   (2*S*)-2-amino-4-\[hydroxy\[hydroxy(4-hydroxy-3-methoxy-5-nitro-phenyl)methyl\]phosphoryl\]butanoic acid

LSP2-9166

:   (2S)-2-amino-4-(((4-(carboxymethoxy)-3-(trifluoromethoxy)phenyl)(hydroxy)methyl)(hydroxy)phosphoryl)butanoic acid

LSP4-2022

:   (2*S*)-2-amino-4-({\[4-(carboxymethoxy)phenyl\](hydroxy)methyl}(hydroxy)phosphoryl)butanoic acid

LTD

:   long-term depression

LTP

:   long-term potentiation

LY341495

:   (2*S*)-2-amino-2-\[(1*S*,2*S*)-2-carboxycycloprop-1-yl\]-3-(xanth-9-yl)propanoic acid

MacMARCKS

:   macrophage myristoylated alanine-rich C-kinase substrate

MDS

:   *MECP2* Duplication syndrome

MeCP2

:   methyl-CpG binding protein 2

mGlu

:   metabotropic glutamate receptor

MMPIP

:   6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo\[4,5-*c*\]pyridin-4(5*H*)-one

MRG

:   mortality factor-related gene

NAM

:   negative allosteric modulator

NDDs

:   neurodevelopmental disorders

NK1

:   neurokinin-1 receptor

OLM

:   oriens-lacunosum-moleculare

PAM

:   positive allosteric modulator

PICK1

:   protein interacting with C kinase 1

PIH

:   phosphatidylinositol hydrolysis

PKA

:   protein kinase A

PKC

:   protein kinase C

PLC

:   phospholipase C

PTZ

:   pentylenetetrazole

RTT

:   Rett syndrome

SC-CA1

:   Schaffer Collateral-CA1

SLIN

:   stratum lucidum interneuron

SNP

:   single nucleotide polymorphism

VFD

:   Venus flytrap domain

VU6005649

:   3-(2,3-difluoro-4-methoxy-phenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo\[1,5-*a*\]pyrimidine
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:   3,4-dimethoxy-*N*-\[2-(1*H*-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl\]benzamide

XAP044
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